Search research articles
Contact Us
Filters
Showing results (41-50 of 54) with videos related to
Page
of 6
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2016
A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC)
E Oki, A Murata, K Yoshida, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
ARCAD-Asia initiative: leveraging yesterday's data for tomorrow
Y Takeda, T Misumi, H Bando, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Recurrence monitoring using ctDNA in patients with metastatic colorectal cancer: COSMOS-CRC-03 and AURORA studies
E Oki, R Nakanishi, K Ando, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 4, 2018
REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients
K Shitara, T Yamanaka, T Denda, et al.
ESMO Open
|
October 9, 2021
Effects of an elemental diet to reduce adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil: a phase III randomized controlled trial-EPOC 2 (JFMC49-1601-C5)
Y Tanaka, H Takeuchi, Y Nakashima, et al.
Transplantation Proceedings
|
March 31, 2015
Prognostic impact of des-γ-carboxyl prothrombin in living-donor liver transplantation for recurrent hepatocellular carcinoma
N Harimoto, Y Yoshida, T Kurihara, et al.
ESMO Open
|
March 21, 2021
Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7
T Takahashi, K Yamazaki, E Oki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 30, 2020
Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial
K Yamazaki, T Yamanaka, M Shiozawa, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Phase III trial of short-course radiotherapy followed by CAPOXIRI versus CAPOX in locally advanced rectal cancer: the ENSEMBLE trial
J Watanabe, Y Kagawa, K Chida, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
VOLTAGE-2: multicenter phase II study of nivolumab monotherapy in patients with mismatch repair-deficient resectable locally advanced rectal cancer
H Bando, Y Tsukada, S Kumagai, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 54) with videos related to
Sort By:
Page
of 6
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2016
A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC)
E Oki, A Murata, K Yoshida, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
ARCAD-Asia initiative: leveraging yesterday's data for tomorrow
Y Takeda, T Misumi, H Bando, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Recurrence monitoring using ctDNA in patients with metastatic colorectal cancer: COSMOS-CRC-03 and AURORA studies
E Oki, R Nakanishi, K Ando, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 4, 2018
REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients
K Shitara, T Yamanaka, T Denda, et al.
ESMO Open
|
October 9, 2021
Effects of an elemental diet to reduce adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil: a phase III randomized controlled trial-EPOC 2 (JFMC49-1601-C5)
Y Tanaka, H Takeuchi, Y Nakashima, et al.
Transplantation Proceedings
|
March 31, 2015
Prognostic impact of des-γ-carboxyl prothrombin in living-donor liver transplantation for recurrent hepatocellular carcinoma
N Harimoto, Y Yoshida, T Kurihara, et al.
ESMO Open
|
March 21, 2021
Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7
T Takahashi, K Yamazaki, E Oki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 30, 2020
Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial
K Yamazaki, T Yamanaka, M Shiozawa, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Phase III trial of short-course radiotherapy followed by CAPOXIRI versus CAPOX in locally advanced rectal cancer: the ENSEMBLE trial
J Watanabe, Y Kagawa, K Chida, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
VOLTAGE-2: multicenter phase II study of nivolumab monotherapy in patients with mismatch repair-deficient resectable locally advanced rectal cancer
H Bando, Y Tsukada, S Kumagai, et al.
Page
of 6